Oxford Biomedica signs licence, supply deal with Cabaletta Bio
Oxford Biomedica
201.00p
17:10 28/03/24
1.93%
3.80p
Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
FTSE 250
19,884.73
17:14 28/03/24
n/a
n/a
FTSE 350
4,383.21
17:14 28/03/24
n/a
n/a
FTSE All-Share
4,338.05
16:50 28/03/24
n/a
n/a
Pharmaceuticals & Biotechnology
21,366.25
17:14 28/03/24
-0.23%
-48.29
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.
No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured”.